Marker Therapeutics, Inc. (MRKR)

Over the past six months, Marker Therapeutics' stock has been influenced by several events. Encouraging Phase 1 APOLLO data for MT-601 in relapsed B cell lymphomas was reported. The company reported its year-end 2025 corporate and financial results, with revenue of $3.55 million and losses of -$12.16 million. Marker Therapeutics presented at healthcare conferences and announced the first patient treated in its Off-the-Shelf program. A Baylor College of Medicine pancreatic cancer study featuring Marker Therapeutics' MAR-T Cell Technology was highlighted. The stock price has decreased by 2.0% since the start of the year, but has increased by 67.82% over the past six months.

As a clinical-stage immuno-oncology company, Marker Therapeutics is primarily focused on research, development, and clinical trials, making traditional demand seasonality not directly applicable. The company's revenue is primarily generated through partnerships, grants, and potential future commercialization.

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing and commercializing T cell-based immunotherapies for hematological malignancies and solid tumors. Their core technology, MAR-T cell therapy, involves expanding non-engineered, tumor-specific T cells to recognize multiple tumor-associated antigens. Key product candidates include MT-601, in Phase 1 trials for lymphoma and pancreatic cancer, and MT-401-OTS, an "Off-the-Shelf" product in Phase 1 for AML and myelodysplastic syndromes.

Marker Therapeutics, Inc. is headquartered in Houston, Texas, and its development and commercialization efforts are focused within the United States.

Marker Therapeutics' brand reputation has been positively influenced by encouraging Phase 1 APOLLO study data for MT-601, highlighting favorable response rates and a good safety profile. The company's MAR-T cell technology was featured on Good Morning America in connection with a promising pancreatic cancer study. The advancement of its Off-the-Shelf program also demonstrates progress and potential for broader patient access.

Marker Therapeutics, Inc. has significant institutional ownership, with 38 institutional owners and shareholders holding 3,866,029 shares as of May 8, 2026. Major institutional shareholders include NEA Management Company, LLC, Blue Owl Capital Holdings LP, and Vanguard Group Inc. Institutional ownership accounts for approximately 23.5% of the company, while individuals hold about 6.0%.